Top

Published in:

Open Access 01-11-2018 | Clinical trial

Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer

Authors: Bihong T. Chen, Taihao Jin, Sunita K. Patel, Ningrong Ye, Can-Lan Sun, Huiyan Ma, Russell C. Rockne, James C. Root, Andrew J. Saykin, Tim A. Ahles, Andrei I. Holodny, Neal Prakash, Joanne Mortimer, James Waisman, Yuan Yuan, Daneng Li, George Somlo, Jessica Vazquez, Abrahm Levi, Heidi Tan, Richard Yang, Vani Katheria, Arti Hurria

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Abstract

Purpose

The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy in older women with breast cancer.

Methods

We recruited 16 women aged ≥ 60 years with stage I–III breast cancers receiving adjuvant chemotherapy (CT) and 15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry.

Results

The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically significantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, and left middle temporal gyrus (p_{FWE(family-wise error)-corrected} < 0.05). The baseline GMD in left insula was positively correlated with the baseline list-sorting working memory score in the HC group (p_{FWE-corrected} < 0.05). No correlation was observed for the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (p_{FWE-corrected} < 0.05).

Conclusions

Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is registered on ClinicalTrials.gov (NCT01992432).

Hurria A, Somlo G, Ahles T (2007) Renaming “chemobrain”. Cancer Invest 25(6):373–377. https://doi.org/10.1080/07357900701506672 CrossRefPubMed

Saykin AJ, de Ruiter MB, McDonald BC, Deprez S, Silverman DH (2013) Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research. Brain Imaging Behav 7(4):363–373. https://doi.org/10.1007/s11682-013-9283-7 CrossRefPubMedPubMedCentral

Simo M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J (2013) Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev 37(8):1311–1321. https://doi.org/10.1016/j.neubiorev.2013.04.015 CrossRefPubMed

Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20–37. https://doi.org/10.1634/theoncologist.12-1-20 CrossRefPubMed

McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2012) Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol 30(20):2500–2508. https://doi.org/10.1200/JCO.2011.38.5674 CrossRefPubMedPubMedCentral

McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123(3):819–828. https://doi.org/10.1007/s10549-010-1088-4 CrossRefPubMedPubMedCentral

McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ (2013) Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 30 Suppl:S117–S125. https://doi.org/10.1016/j.bbi.2012.05.007 CrossRef

Lepage C, Smith AM, Moreau J, Barlow-Krelina E, Wallis N, Collins B, MacKenzie J, Scherling C (2014) A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus 3:444. https://doi.org/10.1186/2193-1801-3-444 CrossRefPubMedPubMedCentral

Chen BT, Sethi SK, Jin T, Patel SK, Ye N, Sun CL, Rockne RC, Haacke EM, Root JC, Saykin AJ, Ahles TA, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Somlo G, Li D, Yang R, Tan H, Katheria V, Morrison R, Hurria A (2018) Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study. Breast Cancer Res 20(1):38. https://doi.org/10.1186/s13058-018-0965-3 CrossRefPubMedPubMedCentral

10.

Ashburner J, Friston KJ (2009) Computing average shaped tissue probability templates. Neuroimage 45(2):333–341. https://doi.org/10.1016/j.neuroimage.2008.12.008 CrossRefPubMed

11.

Ashburner J (2009) Computational anatomy with the SPM software. Magn Reson Imaging 27(8):1163–1174. https://doi.org/10.1016/j.mri.2009.01.006 CrossRef

12.

Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, Carlozzi NE, Slotkin J, Blitz D, Wallner-Allen K, Fox NA, Beaumont JL, Mungas D, Nowinski CJ, Richler J, Deocampo JA, Anderson JE, Manly JJ, Borosh B, Havlik R, Conway K, Edwards E, Freund L, King JW, Moy C, Witt E, Gershon RC (2013) Cognition assessment using the NIH toolbox. Neurology 80(11 Suppl 3):S54–S64. https://doi.org/10.1212/WNL.0b013e3182872ded CrossRefPubMedPubMedCentral

13.

Li M, Caeyenberghs K (2018) Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci Biobehav Rev 92:304–317. https://doi.org/10.1016/j.neubiorev.2018.05.019 CrossRefPubMed

14.

Scherling CS, Smith A (2013) Opening up the window into “chemobrain”: a neuroimaging review. Sensors 13(3):3169–3203. https://doi.org/10.3390/s130303169 CrossRefPubMed

15.

Kesler SR, Kent JS, O’Hara R (2011) Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 68(11):1447–1453. https://doi.org/10.1001/archneurol.2011.245 CrossRefPubMedPubMedCentral

16.

McDonald BC, Saykin AJ (2013) Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations. Brain Imaging Behav 7(4):374–387. https://doi.org/10.1007/s11682-013-9256-x CrossRefPubMed

17.

Lopez Zunini RA, Scherling C, Wallis N, Collins B, Mackenzie J, Bielajew C, Smith AM (2013) Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav 7(4):460–477. https://doi.org/10.1007/s11682-012-9213-0 CrossRefPubMed

18.

Andryszak P, Wilkosc M, Izdebski P, Zurawski B (2017) A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy. Contemp Oncol 21(1):6–15. https://doi.org/10.5114/wo.2017.66652 CrossRef

19.

Reuter-Lorenz PA, Cimprich B (2013) Cognitive function and breast cancer: promise and potential insights from functional brain imaging. Breast Cancer Res Treat 137(1):33–43. https://doi.org/10.1007/s10549-012-2266-3 CrossRefPubMed

20.

Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, Hayes DF, Noll DC, Peltier S, Welsh RC (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32(3):324–331. https://doi.org/10.1080/13803390903032537 CrossRefPubMed

Title: Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer
Authors: Bihong T. Chen
Taihao Jin
Sunita K. Patel
Ningrong Ye
Can-Lan Sun
Huiyan Ma
Russell C. Rockne
James C. Root
Andrew J. Saykin
Tim A. Ahles
Andrei I. Holodny
Neal Prakash
Joanne Mortimer
James Waisman
Yuan Yuan
Daneng Li
George Somlo
Jessica Vazquez
Abrahm Levi
Heidi Tan
Richard Yang
Vani Katheria
Arti Hurria
Publication date: 01-11-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4911-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis

Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI

Pure or mixed-type classical invasive lobular carcinoma might show different imaging features

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy

Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases

The association between estrogen receptor alpha gene rs746432 polymorphism and the risk of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer